GlassScriptPhysician profile
George Waldon Garriss
NPI 1760687131
$506.72
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $82.91 · 2021: $122 · 2022: $171.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $127.31 | 2019-2022 | |
| Amgen INC. | $121.78 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.39 | 2021-2022 | |
| Amarin Pharma, INC. | $31.00 | 2019-2021 | |
| Eisai INC. | $24.54 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $23.02 | 2022 | |
| Shield Therapeutics INC | $18.49 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.73 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.70 | 2022 | |
| Becton, Dickinson and Company | $15.75 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.41 | 2019 | |
| Abbvie INC. | $15.23 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.33 | 2020 | |
| Radius Health, INC. | $12.78 | 2020 | |
| Sunovion Pharmaceuticals INC. | $11.77 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $11.49 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Garriss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.